Core Viewpoint - Amgen plans to invest over $600 million in a new center for science and innovation at its headquarters in Thousand Oaks, California, which is expected to create hundreds of jobs in the U.S. [1][5] Investment and Economic Impact - The new center aims to enhance collaboration among researchers, engineers, and scientists to accelerate the discovery of next-generation therapeutics [2] - Amgen has invested more than $40 billion in manufacturing and R&D in the U.S. since the Tax Cuts and Jobs Act (TCJA) of 2017, including over $5 billion in direct capital expenditures [3] - The enactment of pro-growth tax policies has facilitated Amgen's ability to invest domestically in cutting-edge science and manufacturing [3] Company Commitment and Future Plans - The new center will empower scientists with advanced tools and a collaborative environment to drive scientific excellence [4] - Construction is expected to begin in Q3 2025, further building on Amgen's recent investments, including a $900 million expansion in Central Ohio and a $1 billion investment for a second manufacturing plant in North Carolina [5] Company Background and Recognition - Amgen has been a pioneer in the biotechnology industry for over 40 years, focusing on innovative medicines for serious diseases [6] - The company has received accolades such as being named one of the "World's Most Innovative Companies" and "America's Best Large Employers" [7]

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submissio ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission- ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/ ...

BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ETSeptember 02, 2025 8:30 AM EDT | Source: BioHarvest Sciences Inc.Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time ...

Core Insights - Eupraxia Pharmaceuticals announced positive clinical data from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE), showing promising results at 52 weeks post-treatment [1][2]. Clinical Trial Results - The RESOLVE trial demonstrated that patients receiving 4mg of EP-104GI showed clinical remission rates of 56% at Week 12, 78% at Week 24, 67% at Week 36, and 67% at Week 52 [3]. - Two-thirds of patients in the 48mg dose cohort maintained clinical remission after 12 months, indicating durable treatment effects [7]. - Improvements in tissue health were observed across all cohorts, with significant reductions in EoE Histological Scoring System (EoEHSS) scores, showing a 47% improvement in severity and a 44% improvement in extent at Week 36 [8]. Pharmacokinetics - Plasma levels of fluticasone in patients treated with 4mg of EP-104GI remained stable and predictable over 52 weeks, significantly lower than levels typically seen with daily asthma inhalers [9][11]. Market Potential - The treatment regimen for EP-104GI could align with the annual endoscopy routine for EoE patients, contrasting with current treatments that require daily or weekly administration [2]. - EoE affects over 450,000 individuals in the U.S., with increasing incidence and prevalence, highlighting a significant market opportunity for effective treatments [17]. Company Overview - Eupraxia Pharmaceuticals focuses on developing locally delivered, extended-release products targeting high unmet medical needs, utilizing its proprietary Diffusphere™ technology for optimized drug delivery [18][19].

PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will participate in the 27th Annual H.C. Wainwright Global Investment Conference, to be held in New York, NY and virtually September 8-10, 2025. Frank Bedu-Addo, Ph.D., Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, w ...

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY. H.C. Wainwright 27th Annual Global Investment ConferenceCompany presentation: September 8, 2025, at 1:00 PM ET. Webcast: HEREThe live and archived webcast will also be avai ...

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participa ...